What Happens to Your Sleep Apnea When You Stop a GLP-1 Weight-Loss Drug
Sleep apnea after stopping GLP-1 tracks your weight back up on a timeline you can plan for
Weight regain starts the week you stop and the airway follows. Here is the rebound arc, the European re-test rule, and what to keep in place until your repeat sleep study.
What happens to sleep apnea after stopping GLP-1 treatment
Sleep apnea after stopping GLP-1 treatment follows your weight, not the calendar. Randomised withdrawal trials show weight regain begins immediately after the last dose, so the airway improvement you gained was borrowed rather than banked. Here is the limit no other guide states plainly: no trial has ever measured the apnea-hypopnea index (AHI), the count of breathing pauses per hour, after tirzepatide was withdrawn. What is measured is the link between weight and breathing. A 10% weight gain predicted roughly a 32% rise in AHI in the Wisconsin Sleep Cohort (Peppard et al., JAMA, 2000).
The answer is not "it comes back on day 14". Risk climbs in step with regained kilograms, and symptoms move before any number does. Our review of what the tirzepatide sleep trials actually measured covers the on-treatment side. This page covers sleep apnea after stopping GLP-1 therapy.
- Your apnoea risk tracks regained weight, not the date of your last injection.
- Regain starts immediately, so plan before you stop.
- No trial has measured AHI after a GLP-1 receptor agonist was withdrawn.
Why the improvement was borrowed rather than banked
These medicines never treated your airway. They treated your weight, and the airway responded. Parapharyngeal fat, tongue fat volume and neck circumference shrink as body mass falls, lowering upper airway collapsibility, the pressure at which the throat closes, known as Pcrit. Restore the fat and the advantage goes with it.
The on-treatment effect was large. In SURMOUNT-OSA, a GIP/GLP-1 dual agonist cut mean AHI by up to 62.8% against placebo, about 30 fewer breathing events per hour. Mean AHI fell 27.4 events per hour versus 4.8 on placebo in Study 1, and on the highest dose 43.0% (Study 1) and 51.5% (Study 2) met criteria for disease resolution (SURMOUNT-OSA, New England Journal of Medicine, 2024).
European specialists read it cautiously. The ERS/ESRS pro-con debate in European Respiratory Review (2026) cites AHI reductions of 20 and 24 events per hour, names post-discontinuation weight regain as a reason for caution, and concludes GLP-1 use should complement CPAP rather than replace it.
- The mechanism was fat loss around the airway, not a respiratory effect.
- SURMOUNT-OSA measured 52 weeks on the drug and nothing after it.
- In Europe the medicine sits alongside CPAP, not in place of it.
The rebound timeline for sleep apnea after stopping GLP-1
No competing page answers this. The arc below comes from the withdrawal trials; the airway column is inference, not measurement.
In SURMOUNT-4, participants lost a mean 20.9% of body weight over 36 weeks. Those switched to placebo regained 14% over the next 52 weeks, while those continuing lost a further 5.5% (narrative review of randomised withdrawal studies, Journal of Clinical Medicine, 2025). The same review reports the STEP 1 extension: 11.6 percentage points of lost weight regained in the 52 weeks after semaglutide was withdrawn.
| Time since last dose | What the withdrawal trials document | Likely airway effect (inferred) |
|---|---|---|
| Weeks 1-4 | Appetite signalling returns; regain begins immediately after cessation (SURMOUNT-4, 2025) | Too little weight change to shift AHI. Snoring unchanged. |
| Months 1-3 | Trials measured at 52 weeks, not monthly, so this row is interpolated | Partners commonly notice snoring before the scales alarm you. |
| Months 3-6 | Regain is under way in every withdrawal arm reviewed (SURMOUNT-4, STEP 1, STEP 4) | Approaching the 10% threshold where AHI change becomes predictable. |
| Months 6-12 | Half of SURMOUNT-4 participants regained more than 50% of lost weight, at least a quarter more than 75% (Horn et al., JAMA Internal Medicine, 2025) | When residual obstructive sleep apnoea most often turns symptomatic again. |
| Beyond 12 months | In STEP 4 the placebo-switch group gained 6.9% while those continuing lost 7.9% more (2025 review) | Retesting is overdue once weight has moved 10% or more. |
Regain is not uniform. Comparing those regaining under 50% of lost weight with those regaining over 75%, waist circumference moved +0.8 cm versus +14.7 cm (Horn et al., European Society of Cardiology, 2025). Waist and neck fat are the compartments that matter for breathing.
- Regain starts within weeks; symptoms usually surface between months three and twelve.
- Anyone naming a precise week when apnoea returns is guessing.
What regaining 10% of your body weight does to your AHI
No competing page performs this conversion. The Wisconsin Sleep Cohort followed 690 adults at four-year intervals: a 10% weight gain predicted a 32% increase in AHI (95% CI, 20-45%), and those adults had six times the odds of newly meeting moderate-to-severe sleep-disordered breathing criteria, meaning an AHI of 15 or more (Peppard et al., JAMA, 2000). A 10% loss predicted a 26% decrease.
Apply that to a real stop. If you weighed 95 kg at your last injection, 10% is 9.5 kg. Regain it, and that cohort figure predicts your AHI rises by about a third. An AHI of 9 would land near 12. An AHI of 14 would land near 18, inside the moderate band. That is a population association, not a promise about your night. Still, it is the only quantified bridge between the scale and your indice d'apnées-hypopnées (IAH).
Surgical data agrees. Five years after bariatric surgery, with mean weight loss of 22.2%, mean AHI fell from 27.8 to 8.8 events per hour and 55% of patients were cured below an AHI of 5. Moderate or severe disease still persisted in 20% (prospective multicentre trial, Obesity Surgery, 2024). Durable loss clears many people, not everybody. Our breakdown of how much weight loss reverses sleep apnea works through those thresholds.
- Ten percent regained predicts roughly a third more breathing events per hour.
- Six times the odds of newly qualifying as moderate-to-severe.
- Even durable surgical loss left one in five with moderate or severe disease at five years.
What most guides on stopping a GLP-1 get wrong
Most advice on sleep apnea after stopping GLP-1 medication fails in two specific ways.
Flaw one: every stopping section is about stopping CPAP
Guides advise carefully on handing the machine back, never on getting it back. That asymmetry matters in Europe. In France, PPC (pression positive continue) is a rented, tele-monitored service from a prestataire, not a device you buy. Restarting means a fresh prescription and a provider set-up, measured in weeks. Our guide to coming off CPAP after weight loss explains the exit. Re-entry is the part the internet ignores.
Flaw two: the binary framing
Pages present two states, on the drug or off it. The airway question is different. Does a lower maintenance dose that holds weight steady also hold AHI steady? Nobody has tested that endpoint. Because AHI tracks weight, tapering to a dose that stops regain is worth raising with your prescriber before cost or supply decides for you.
- Know your restart route before you stop, not after symptoms return.
- Ask about tapering instead of accepting an all-or-nothing choice.
Why European patients stop, and why the date is often not theirs
Most European discontinuations are administrative, not clinical. In a Danish population study of 77,310 people without diabetes using semaglutide for weight loss, discontinuation rose from 18% at three months to 52% at twelve months (European Association for the Study of Diabetes, 2025).
| Where you are | What ends treatment | The rule that decides it |
|---|---|---|
| France | Eligibility and continuation review | Reimbursable since 15 June 2026 at a BMI (IMC) of 40 or above, or 35 or above with a comorbidity; SAHOS counts only at an IAH of 15/h or higher. Six prior months of nutritional management yielding under 5% loss are required. Cover is 65% in ville, effectively 100% under ALD (affection de longue durée). French sources describe continuation conditioned on 5% loss at a four-month review. |
| Germany | Blanket statutory exclusion | GLP-1s prescribed for weight reduction are excluded from statutory cover as Lifestyle-Arzneimittel under §34 Abs. 1 Satz 7 SGB V, enacted through the G-BA's Arzneimittel-Richtlinie. Patients get a Privatrezept and pay up to roughly €490 per month. Cost-driven stopping is the default German pathway. |
| United Kingdom | Phased rollout cohorts | NICE TA1026 lists obstructive sleep apnoea among qualifying weight-related conditions but staggers access: BMI 40 or above with four or more conditions first, widening around June 2026 to BMI 35-39.9 with four or more, and around March 2027 to three or more. An estimated 220,000 people are treated in the first three years. |
| EU-wide | Supply interruption | GLP-1 receptor agonist shortages have run since 2022. The EMA's Medicine Shortages Steering Group told Member States to prioritise patients with the greatest need. The semaglutide shortage was listed as resolved in January 2026. |
The consequence is scheduling. If a review, a bill or a shortage can end treatment on a date you do not control, your airway plan has to exist before it arrives.
- Half of non-diabetic semaglutide users had stopped by twelve months in the Danish data.
- France, Germany and the UK each impose a different administrative stop-trigger.
When to get retested, and with which test
There is a concrete rule, and almost nobody quotes it. Follow-up polysomnography or a home sleep apnoea test (HSAT) may be used when clinically significant weight gain or loss of 10 to 20% has occurred since the diagnosis of OSA or since treatment started, while routine reassessment of asymptomatic patients on positive airway pressure is not recommended (American Academy of Sleep Medicine, Journal of Clinical Sleep Medicine, 2021).
So you have a trigger you can watch. Weigh weekly after the last dose, and write down what 10% of that weight is.
- Record your weight, Epworth Sleepiness Scale score and your partner's snoring report in the week you stop. That is your baseline.
- Re-weigh weekly. Contact your prescriber or centre du sommeil when regain reaches 10%, or sooner if daytime sleepiness returns.
- Ask for polygraphie ventilatoire nocturne or an HSAT first. In-lab polysomnography is for complex or discordant cases.
- Get the AHI and the oxygen desaturation index (ODI) in writing, so the next comparison is like-for-like.
- If your pre-treatment AHI was 30 or above, book the review when you stop rather than waiting for symptoms.
Restarting CPAP is not a same-day purchase
In France, continued PPC cover is tied to observance of at least four hours per night, recorded by télésuivi and sent to l'Assurance Maladie, reimbursed at 60% of the weekly forfait or 100% under ALD. The Cour de cassation has held that, as the law stands, reimbursement cannot be conditioned on observance. Either way, returning the machine means a new prescription and a prestataire appointment. Start early. A mandibular advancement device (orthèse d'avancée mandibulaire, or OAM) is a second route for mild-to-moderate disease, but it is dentist-fitted and also takes weeks.
- The retest trigger is a 10-20% weight change, in either direction.
- Record weight, Epworth score and snoring on the day you stop.
Your plan between the last dose and the repeat test
The riskiest stretch of sleep apnea after stopping GLP-1 therapy is the wait for a test nobody has booked yet. Five things are worth doing tonight.
1Set a weight floor, not a weight goal
Choose a ceiling a few kilograms above your stopping weight, well short of the 10% regain that predicts an AHI rise, and treat crossing it as an alarm. Protein and resistance training matter here, because rapid regain tends to restore fat before lean mass, and sarcopenic regain worsens the body composition linked to your apnoea.
2Use position deliberately
Positional therapy is free. If your sleep report showed a supine AHI far above your side-sleeping AHI, avoiding your back is a real intervention, not a folk remedy. Treat head-of-bed elevation as comfort, not a proven substitute.
3Move alcohol and sedatives away from bedtime
Both relax the pharyngeal muscles and raise collapsibility, exactly as your protective weight loss unwinds. A clear gap between your last drink and lights out costs nothing.
4Fix nasal breathing before blaming the throat
A blocked nose can raise the negative pressure pulling the airway shut downstream. Treat rhinitis, allergy or congestion now. It removes one variable while everything else is in flux, though it will not resolve obstructive apnoea alone.
5Know your urgent triggers
Routine referral covers returning snoring and mild excessive daytime sleepiness. Seek urgent review for witnessed apnoeas with choking, morning headaches with rising blood pressure, sleepiness at the wheel, or new cardiac symptoms.
- A weight floor beats a weight goal during the rebound window.
- Position, alcohol timing and nasal patency are the three free levers.
Where a nasal stent fits in that gap
A nasal stent is a night-by-night bridge, not a treatment decision. The honest case is narrow: your snoring and mild-to-moderate apnoea improved on the drug, you are stopping for cost or a payer review, and weeks stand between the last dose and a repeat polygraphie.
The published evidence for nasopharyngeal stents is small, and deserves quoting that way. Studies of this device class report mean AHI falling from about 22.4 to 15.7 events per hour, and from about 25.8 to 19.5, with roughly a quarter of users becoming complete responders and around 30% unable to tolerate it. Modest averages, real dropout, no cure.
Back2Sleep is a CE-certified Class I soft silicone intranasal stent from a French company based in Paris. It holds the nasal airway open during sleep, needs no prescription, no electricity and no tubing, and the starter kit contains four sizes for around €39. Low cost and immediate availability are the point here.
- Use it as a bridge for mild-to-moderate disease during the wait, nothing more.
- The stent evidence is modest, with roughly 30% intolerance.
What Back2Sleep Users Say
Frequently Asked Questions
Will my sleep apnea come back if I stop Mounjaro or Wegovy?
Probably, in proportion to the weight you regain. Withdrawal trials show regain starts immediately after the last dose, and a 10% weight gain predicted a 32% rise in AHI (Peppard, JAMA, 2000). No trial has measured AHI directly after tirzepatide withdrawal, so treat any precise timeline with caution.
How long after stopping a GLP-1 does the weight come back?
Immediately, then steadily. In SURMOUNT-4, people switched to placebo regained 14% of body weight over the next 52 weeks (Journal of Clinical Medicine review, 2025), and within a year half had regained more than 50% of what they lost (Horn et al., JAMA Internal Medicine, 2025). Weigh weekly.
Do I need a new sleep study after losing weight on a GLP-1?
Yes, once your weight has changed by 10 to 20% since diagnosis or since treatment started. That is the American Academy of Sleep Medicine threshold (2021) for repeating polysomnography or a home sleep apnoea test. Routine retesting of asymptomatic patients already using CPAP is not recommended.
How much weight regain makes sleep apnea worse again?
Ten percent is the number that matters. In the Wisconsin Sleep Cohort, a 10% weight gain predicted a 32% increase in AHI and six times the odds of newly meeting moderate-to-severe criteria (Peppard et al., JAMA, 2000). For a 95 kg person that is 9.5 kg.
Is there a lower maintenance dose that keeps sleep apnea away?
No trial has measured AHI on a reduced maintenance dose, so nobody can promise this. What is known is that AHI tracks body weight, and that people who continued treatment in SURMOUNT-4 and STEP 4 kept losing weight rather than regaining it. Ask your prescriber about tapering before cost forces a full stop.
Can a home sleep apnoea test replace polysomnography after stopping a GLP-1?
Often, yes. A home sleep apnoea test or polygraphie ventilatoire nocturne is usually the first step for straightforward obstructive cases, with in-lab polysomnography reserved for complex or discordant results. Ask for your AHI and oxygen desaturation index in writing so the next comparison is like-for-like.
Is Mounjaro reimbursed for sleep apnoea in France or Germany?
Not for apnoea itself. In France, reimbursement since 15 June 2026 covers obesity, where SAHOS with an IAH of 15/h or higher can qualify as the comorbidity. In Germany, weight-reduction GLP-1s are excluded from statutory cover as lifestyle medicines, so patients pay privately.
What happens to snoring when you stop Ozempic?
Snoring often returns before any measured number changes, and a partner usually notices first. It tracks returning fat around the pharynx as weight climbs back. Louder snoring, witnessed pauses or morning headaches after stopping are reasons to contact your doctor rather than to wait for the next appointment.
Ready for quieter nights? Discover the Back2Sleep starter kit and find the right fit for you.
Not sure if you are at risk? Take our sleep risk screening to find out in just a few minutes.
Want to learn how it works? Explore the Back2Sleep nasal stent designed for comfortable, effective relief.